NCT07439653ClinicalTrials.gov
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
باختصار
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
المرحلة 1 / المرحلة 2مطلوب 155 مشاركاً9 مواقعدولة واحدة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07439653فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل شهرين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-02-27; recorded start 2026-03-31
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 9 other studies in this databaseCounted from the lead sponsor named in the record (TORL Biotherapeutics, LLC)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Non-randomised allocation
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre5/8
Multi-centre: 3 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study: 155 participants (target), run at 9 sites.
How this score is built
- Enrolment21/40
155 participants (target)
- Site count6/25
3 sites
- Country count0/15
Single country
- Planned duration9/10
Planned over about 43 months
- Sponsor scale3/10
TORL Biotherapeutics, LLC has led 10 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
الحالات
- Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 1 / المرحلة 2 |
| التخصيص | غير معشّاة |
| نموذج التدخّل | SEQUENTIAL |
| الغرض الأساسي | TREATMENT |
| التعمية | NONE (0) |
| التجنيد | مطلوب 155 مشاركاً |
الجهة الراعية والمتعاونون
- TORL Biotherapeutics, LLC الجهة الراعية
الأذرع والتدخلات
- Part 1: Monotherapy Dose EscalationEXPERIMENTAL
TORL-5-700 Administered once every three weeks
- Part 2: Monotherapy ExpansionEXPERIMENTAL
TORL-5-700 at MTD/RP2D Administered once every three weeks
- Part 3: Combination EvaluationEXPERIMENTAL
TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent
التدخلات
- دواء TORL-5-700
Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks
- دواء TORL-5-700 at MTD/RP2D
Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks
- دواء TORL-5-700 at MTD/RP2D in combination with another agent
Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent
مقاييس النتائج
مقياس النتيجة الأولي
Evaluate the safety of TORL-5-700 as a monotherapy
Assessment of adverse events according to NCI-CTCAE Version 5.0
الإطار الزمني though study completion, an average of 2.5 years
مقياس النتيجة الأولي
Assess the antitumor activity of TORL-5-700 as monotherapy
Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria
الإطار الزمني though study completion, an average of 2.5 years
مقياس النتيجة الأولي
Evaluate the safety of TORL-5-700 in combination with other agents
Assessment of adverse events according to NCI-CTCAE Version 5.0
الإطار الزمني though study completion, an average of 2.5 years
مقياس النتيجة الأولي
Determine the Maximum Tolerated Dose (MTD)
Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)
الإطار الزمني 21 days from the start of treatment
مقياس النتيجة الأولي
Determine the Recommended Phase 2 Dose (RP2D)
Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities
الإطار الزمني 21 days from the start of treatment
مقياس النتيجة الثانوي
Maximum Serum Concentration of TORL-5-700 (Cmax)
Pk assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents
Pk assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Terminal Half-life (t1/2) of Serum TORL-5-700
Pk assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents
Pk assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration
Pk assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents
Pk assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Clearance (CL) of TORL-5-700
Pk assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Clearance (CL) of TORL-5-700 in combination with other agents
Pk assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Volume of distribution of TORL-5-700
PK assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Volume of distribution of TORL-5-700 in combination with other agents
PK assessment
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Immunogenicity of TORL-5-700
Immunogenicity will be measured by incidence of treatment emergent ADAs
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Immunogenicity of TORL-5-700 in combination with other agents
Immunogenicity will be measured by incidence of treatment emergent ADAs
الإطار الزمني though end of study treatment, an average of 5 months
مقياس النتيجة الثانوي
Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents
Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria
الإطار الزمني though study completion, an average of 2.5 years
التواريخ
| تاريخ البدء | 31 مارس 2026 (فعلي) |
|---|---|
| الإتمام الأولي | 31 مارس 2029 (تقديري) |
| الإتمام | 30 سبتمبر 2029 (تقديري) |
| أول نشر | 27 فبراير 2026 (فعلي) |
| آخر تحديث | 28 سبتمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | أغسطس 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
9 مواقع قيد التجنيد
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| University of Texas Southwestern Medical Center | Dallas | Texas | قيد التجنيد |
| Providence Medical Foundation | Fullerton | California | قيد التجنيد |
| University of Iowa Health Care | Iowa City | Iowa | قيد التجنيد |
| Cancer and Blood Specialty Clinic, Los Alamitos | Los Alamitos | California | قيد التجنيد |
| University of California Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | قيد التجنيد |
| Sarah Cannon Research Institute | Nashville | Tennessee | قيد التجنيد |
| UCLA | Santa Monica | California | قيد التجنيد |
| Stanford University | Stanford | California | قيد التجنيد |
| Cancer Center of Kansas, Wichita | Wichita | Kansas | قيد التجنيد |
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 28 سبتمبر 2026
أُضيف موقع
3 sites added (9 total)
69
- 24 أغسطس 2026
أُضيف موقع
3 sites added (6 total)
36